Area:
chemical and systems biology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Rachel Bright is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 2003 — 2005 |
Bright, Rachel |
F31Activity Code Description:
To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.). |
Pkc in Cerebral Ischemic Reperfusion Injury
[unreadable] DESCRIPTION (provided by applicant): [unreadable] Stroke remains the leading cause of disability and the third leading cause of death in the U.S. Although more stroke patients are treated with thrombolytic agents, all neuroprotection trials for stroke have failed so far and therefore, new pharmacological interventions are greatly needed. Protein kinase C (PKC) has been implicated in preservation of various organs from ischemic insults, however many of these studies have focused on cardioprotection. Ischemic episodes to the brain result in activation of several protein kinase C isozymes, however conflicting roles (both positive and negative) for PKC in the response of the brain to ischemic injury have been reported. This is potentially due to the use of pharmacological agents which do not discriminate between the PKC isozymes. I propose that select PKC isozymes play unique roles in the various response stages of cerebral ischemic insult and reperfusion damage. To support this hypothesis I found that delivery of a peptide inhibitor of deltaPKC at the initiation of reperfusion reduces the size of cerebral lesion caused by transient focal ischemia in vivo. In the proposed study I plan to address the molecular mechanism of deltaPKC involvement in cerebral ischemic and reperfusion injury. I will determine the abundance, distribution, and activity of deltaPKC in the brain during a time course of ischemia and reperfusion in a rat model of stroke. I will then analyze whether treatment with deltaPKC specific inhibitor and activator peptides that we have developed, alter the translocation of deltaPKC in vivo. In addition, I will study the affect of deltaPKC modulation on markers of apoptotic cell death. Finally, I plan to investigate the role of other PKC isozymes in ischemic and reperfusion damage by analyzing the effects of our PKC modulating- peptides on cerebral lesion following focal ischemia in vivo. [unreadable] [unreadable]
|
1 |